The appropriate role of cost-effectiveness in determining device coverage: A case study of drug-eluting stents

Health Affairs

Volumn 27, Issue 6, 2008, Pages 1577-1586

  Firth, Brian Garriock ^a   Cooper, Liesl M ^b   Fearn, Steve ^c  

^a Department of Medical Affairs and Health Ecomomics Worldwide   (United States)

^b Global Healthcare Economics Policy and Reimbursement   (United States)

^c JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN; PACLITAXEL; RAPAMYCIN; WARFARIN;

ARTICLE; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEVICE; DRUG ELUTING STENT; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; IN-STENT RESTENOSIS; MEDICAID; MEDICARE; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; STENT; SYSTEMATIC REVIEW; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED KINGDOM; UNSTABLE ANGINA PECTORIS;

ADVISORY COMMITTEES; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; GREAT BRITAIN; ORGANIZATIONAL CASE STUDIES; QUALITY-ADJUSTED LIFE YEARS; REIMBURSEMENT MECHANISMS; STATE MEDICINE;

EID: 56649112774     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.27.6.1577     Document Type: Article

References (31)

1. M.C. Weinstein and W.B. Stason, "Foundations of Cost-Effectiveness Analysis for Health and Medical Practices," New England Journal of Medicine 296, no. 13 (1977): 716-721;
2. and J. Bowen et al., Systematic Review and Cost-Effectiveness Analysis of Drug Eluting Stents Compared to Bare Metal Stents for Percutaneous Coronary Interventions in Ontario: Interim Report, Report no. HTA002-0512, December 2005, http://www.path-hta.ca/DESreport.pdf (accessed 13 August 2008).
3. House of Commons Health Select Committee, National Institute for Health and Clinical Excellence: First Report of Session 2007-08, vol. 1, 17 December 2007, http://www.publications.parliament.uk/pa/cm200708/cmselect/ cmhealth/27/27.pdf (accessed 13 August 2008).
4. NICE, "Ischaemic Heart Disease - Coronary Artery Stents (Review): Appraisal Consultation Document," 2007, http://guidance.nice.org.uk/page. aspx?o=445413 (accessed 13 August 2008).
5. U.K. Parliament, "Heart Diseases: Medical Equipment," 18 December 2007, http://www.publications.parliament.uk/pa/cm200708/cmhansrd/ cm071218/text/71218w0035.htm (accessed 13 August 2008).
6. R.G. Favaloro, "Direct Myocardial Revascularization," Surgical Clinics of North America 51, no. 5 (1971): 1035-1042.
7. A.R. Gruentzig, "Transluminal Dilatation of Coronary Artery Stenosis" (letter), Lancet 1, no. 8058 (1978): 263.
8. P.W. Serruys et al., "A Comparison of Balloon-Expandable Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease," New England Journal of Medicine 331, no. 8 (1994): 489-495;
9. and D.L. Fischman et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease," New England Journal of Medicine 331, no. 8 (1994): 496-501.
10. M.C. Morice et al., "A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization," New England Journal of Medicine 346, no. 23 (2002): 1773-1780;
11. J.W. Moses et al., "Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery," New England Journal of Medicine 349, no. 14 (2003): 1315-1323;
12. and G.W. Stone et al., "A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease," New England Journal of Medicine 350, no. 3 (2004): 221-231.
13. C. Stettler et al., "Outcomes Associated with Drug-Eluting and Bare-Metal Stents: A Collaborative Network Meta-Analysis," Lancet 370, no. 9591 (2007): 937-948.
14. See online Appendix Figure 1 at http://content.healthaffairs.org/cgi/ content/full/27/6/1577/DC1.
15. See online Appendix Figure 2, as above; and Stettler et al., "Outcomes Associated with Drug-Eluting and Bare Metal Stents."
16. NICE, Assessment Report: Coronary Artery Stents Rapid Systematic Review and Economic Evaluation - Addendum B, 24 June 2003, http://www.nice.org.uk/guidance/index.jsp?action=download&o=32772 (accessed 25 February 2008).
17. NICE, "NICE Assessment Report: Coronary Artery Stents for the Prevention of Ischaemic Heart Disease, Comments from the British Cardiac Society; British Cardiovascular Intervention Society; and Royal College of Physicians," January 2006, http://www.nice.org.uk/nicemedia/pdf/ IHDACDCConARBCSandBCIS.pdf (accessed 13 August 2008).
18. U.K. Department of Health, NHS Reference Costs, 2005-06, 7 December 2006, http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH_062884 (accessed 17 January 2008).
19. Weinstein and Stason, "Foundations of Cost-Effectiveness Analysis."
20. D.J. Cohen et al., "Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: Results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions (SIRIUS) Trial," Circulation 110, no. 5 (2004): 508-514;
21. and D.J. Cohen et al., "Cost-Effectiveness of Coronary Stenting in Acute Myocardial Infarction: Results from the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial," Circulation 104, no. 25 (2001): 3039-3045.
22. British Cardiovascular Society response to NICE Assessment Report Supplements 3 and 4, http://www.nice.org.uk/nicemedia/pdf/ IHDACDAddAnalysisBCSandBCIS.pdf (accessed 17 January 2008).
23. Cohen et al., "Cost-Effectiveness of Coronary Stenting."
24. NICE, "Ischaemic Heart Disease - Coronary Artery Stents (Review): Appraisal Consultation Document"; Stettler et al., "Outcomes Associated with Drug-Eluting and Bare Metal Stents"; and BCS response to NICE Assessment Report Supplements 3 and 4.
25. S.D. Reed et al., "Conducting Economic Evaluations alongside Multinational Clinical Trials: Toward a Research Consensus," American Heart Journal 149, no. 3 (2005): 434-443;
26. and D. Greenberg et al., "Willingness to Pay for Avoiding Coronary Restenosis and Repeat Revascularization: Results froma Contingent Valuation Study," Health Policy 70, no. 2 (2004): 207-216.
27. NICE, Assessment Report: Coronary Artery Stents Rapid Systematic Review and Economic Evaluation - Addendum B.
28. UK DOH, NHS Reference Costs, 2005-06.
29. L. Mauri et al., "Long-Term Outcomes following Drug-Eluting and Bare Metal Stenting in Massachusetts" (Presentation at the American Heart Association Scientific Sessions, Orlando, Florida, 2007);
30. and J.V. Tu et al., "Effectiveness and Safety of Drug-Eluting Stents in Ontario," New England Journal of Medicine 357, no. 14 (2007): 1393-1402.
31. BCS response to NICE Assessment Report Supplements 3 and 4.